PHOTOCURE Aktie

 

Oslo, Norway, 23 June 2025 - Photocure ASA (the "Company") (OSE: PHO) has granted share options to employees. A total of 451,000 share options, equal to approx. 1.83% of total shares issued in the Company, were granted to employees at an exercise price at NOK 55.47. The exercise price is equal to the weighted average share price 30 trading days before the day of grant with an additional premium of 10% on top of the calculated average price. The options are granted in accordance with Photocure's long term incentive program and the Company's guidelines for remuneration of senior executives (...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

OSLO, Norway, May 8, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 125.3 million in the first quarter of 2025 (Q1 2024: NOK 116.8 million), and an EBITDA of NOK 1.8 million (7.9) for the company. Photocure expects product revenue growth in......

Oslo, Norway, 5 May 2025: Photocure ASA (OSE: PHO), held its annual general meeting on 5 May 2025 at 17:00 hours (CEST). The minutes from the general meeting setting out the resolutions are attached hereto.   For further information, please contact:   Photocure CFO Erik Dahl Tel: + 47 450 55 000 Email: ed@photocure.no   About Photocure ASA Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, which makes cancer cells glow bright pink, has led to better health outcomes for...

Oslo, Norway, 30 April 2025: Photocure ASA (Photocure, PHO: OSE) will announce the first quarter 2025 financial results on Thursday 8 May 2025 at 07:00 CEST and will present a live webcast at 14:00 CEST the same day. The quarterly report and presentation will be published at 07:00 CEST and will be publicly available at www.photocure.com.   The investor presentation will be streamed live and be hosted by Dan Schneider, CEO and Erik Dahl, CFO. The presentation will be held in English and questions can be submitted throughout the event. The presentation is scheduled to conclude at 14:45...

OSLO, Norway, April 29, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces four abstract presentations at the AUA 2025, highlighting the benefits of Blue Light Cystoscopy (BLC®), notably its impact on management of the disease, improved risk......

Oslo, Norway, 11 April 2025: Photocure ASA (OSE: PHO), calls for the annual general meeting of Photocure ASA to be held on 5 May 2025 at 17:00 hours (CEST), virtual through the general meeting portal administered by Euronext Securities Oslo (the "Euronext Securities Portal"). The general meeting will be webcasted live and a link will be available on the company's website in due time in advance of the general meeting. It will not be possible to attend in person. Shareholders may also vote in advance or submit a proxy with voting instructions. The notice convening the general meeting,...

Oslo, Norway, 11 April 2024: Photocure ASA today announces the publication of the Annual Report and integrated ESG report for 2024. The Board of Directors of Photocure ASA has approved the annual accounts for 2024. The financial statements and annual report for the financial year 2024 are together with the ESG report and auditor's report attached to this notice. The ESEF file for 2024 is also attached. The documents are enclosed and also made available at the company's website under https://photocure.com/investors-hub/investors-events-and-presentations.   For further information,...

Oslo, Norway, 2 April 2025: Reference is made to the stock exchange announcement made by Photocure ASA ("Photocure" or the "Company") on 19 March 2025 of the launch of Photocure's program to repurchase up to 200,000 of its own shares for a total maximum amount of NOK 20 million during the period from 20 March 2025, until no later than the annual general meeting in 2025, pursuant to an agreement with DNB Markets. For the period from and including 19 March 2025, through 1 April 2025, the Company purchased a total of 200,000 shares at an average price of NOK 57.45 per share, all purchased as...

Oslo, Norway, 31 March 2025: Reference is made to the stock exchange announcement made by Photocure ASA ("Photocure" or the "Company") on 19 March 2025 of the launch of Photocure's program to repurchase up to 200,000 of its own shares for a total maximum amount of NOK 20 million during the period from 20 March 2025, until no later than the annual general meeting in 2025, pursuant to an agreement with DNB Markets. PHO: Transactions made under share buyback program   For the period from and including 19 March 2025, through 28 March 2025, the Company purchased a total of 179,648 shares at...

Oslo, Norway, 26 March 2025 - Photocure ASA (the "Company") (OSE: PHO) has granted share options to Jane Healy, the Company's newly appointed Vice President and General Manager EMEA as announced separately by the Company today. A total of 100,000 share options have been issued to Jane Healy at an exercise price of NOK 57.59. The exercise price is equal to the weighted average share price 30 trading days before day of grant with an additional premium of 10% on top of the calculated average price.   The options are granted in accordance with the Company's long term incentive program and...

OSLO, Norway, March 26, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced the appointment of Jane Healy as Vice President and General Manager EMEA. Ms. Healy joined Photocure in March 2025 to lead the European Organization. Her extensive......

OSLO, Norway, March 24, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two abstract presentations at the 2025 European Association of Urology congress (EAU) in Madrid, Spain, highlighting the benefits of Blue Light Cystoscopy (BLC®), notably its......

Oslo, Norway, 19 March 2025: Photocure ASA (the "Company") has decided to initiate a buyback of up to 200,000 of its own shares for a total maximum amount of NOK 20 million. The buyback program may be carried out in the period from this announcement and until 5 May 2025. The buybacks will be made in accordance with the authorisation granted to the board of directors by the Company`s annual general meeting held on 23 May 2024 (the "Authorisation") and in accordance with principles of the Market Abuse Regulation (EU) No 596/2014 and Commission Delegated Regulation (EU) No. 2016/1052 regarding...

OSLO, Norway, March 14, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication of the study "Oncologic Outcomes of Blue Light Cystoscopy in an Equal Access Setting: Results of the BRAVO study" in JU Open Plus this week. The research objective......

OSLO, Norway, March 14, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication of the study "Oncologic Outcomes of Blue Light Cystoscopy in an Equal Access Setting: Results of the BRAVO study" in JU Open Plus this week. The research objective......

Oslo, Norway, 16 January 2025: Reference is made to the stock exchange announcement made by Photocure ASA ("Photocure" or the "Company") on 19 December 2024 of the launch of Photocure's program to repurchase up to 300,000 of its own shares for a total maximum amount of NOK 30 million during the period from 19 December 2024, until no later than 31 March 2025, pursuant to an agreement with DNB Markets. For the period from and including 19 December 2024, through 14 January 2025, the Company purchased a total of 300,000 shares at an average price of NOK 60.41per share, all purchased as ordinary...

Oslo, Norway, 13 January 2025: Reference is made to the stock exchange announcement made by Photocure ASA ("Photocure" or the "Company") on 19 December 2024 of the launch of Photocure's program to repurchase up to 300,000 of its own shares for a total maximum amount of NOK 30 million during the period from 19 December 2024, until no later than 31 March 2025, pursuant to an agreement with DNB Markets. For the period from and including 19 December 2024, through 10 January 2025, the Company purchased a total of 258,670 shares at an average price of NOK 60.97 per share, all purchased as ordinary...

Oslo, 5 January 2025: Reference is made to the stock exchange announcement made by Photocure ASA ("Photocure" or the "Company") on 19 December 2024 of the launch of Photocure's program to repurchase up to 300,000 of its own shares for a total maximum amount of NOK 30 million during the period from 19 December 2024, until no later than 31 March 2025, pursuant to an agreement with DNB Markets. For the period from and including 19 December 2024, through 3 January 2024, the Company purchased a total of 150,802 shares at an average price of NOK 62.43 per share, all purchased as ordinary market...

Oslo, Norway, 23 December - Photocure ASA (the "Company") (OSE: PHO) has granted share options to employees. A total of 633,500 share options, equal to 2.3% of total shares issued in the Company, were granted to employees at an exercise price at NOK 59.57. The exercise price is equal to the weighted average share price 30 trading days before day of grant with an additional premium of 10% on top of the calculated average price. The options are granted in accordance with Photocure's long term incentive program and the Company's guidelines for remuneration of senior executives (the "...